Chemesis International Inc. (the “Company”) (CSE: CSI) (OTC: CADMF) (FRA: CWAA) is pleased to announce that all matters submitted to the shareholders of the Company at the Annual General and Special Meeting of the Company’s shareholders held on December 31, 2020 were approved.
In addition, the Company has granted, pursuant to its Equity Incentive Plan, options to purchase 1,500,000 shares of the Company exercisable for a period of 5 years at USD$0.70 per share to the directors, officers and consultants of the Company. The Company has also granted, pursuant to its Equity Incentive Plan, restricted share rights to acquire 1,500,000 shares of the Company to the directors, officers and consultants of the Company. One-half of such restricted share rights shall vest in three months from the grant date and the remaining one-half shall vest in six months from the grant date.
On Behalf of The Board of Directors
1 (604) 398-3378
The CSE has not reviewed, approved or disapproved the content of this press release
A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.
Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.
Keep reading to find out more cannabis highlights from the past five days.
New HEXO CEO gets confirmed
This past week, HEXO (NASDAQ:HEXO,TSX:HEXO) announced the appointment of Scott Cooper as its new president and CEO. Cooper is an addition from Truss, HEXO’s beverage joint venture with Molson-Coors Canada, where he also serves as president and CEO.
The company announced Cooper will be expected to fill both roles for the next six months as a way to “ensure a smooth transition for the business.”
“I want to thank outgoing CEO Sebastien St-Louis for his tremendous effort in establishing growth and delivering a solid position from which the Company can move forward,” Cooper said.
A report from BNN Bloomberg indicates that an investor letter sent to the HEXO board last month by Adam Arviv directly led to the dismissal of St-Louis.
The letter berates the former executive for “continuously (making) negligent decisions and (delivering) poor financial performance.” In its report, BNN Bloomberg said:
The letter states that St-Louis over-leveraged Hexo to help finance deals to acquire “distressed” cannabis operators Zenabis Global Inc. and 48North Cannabis Corp.
Arviv and the Redecan ownership group cumulatively own about 70 million of Hexo’s shares, making them one of the company’s largest shareholders.
In his departure statement, St-Louis, who founded the company originally, said he is proud of HEXO and thinks the future of the company is bright. “As a significant shareholder I look forward to the Company’s next exciting stage of growth,” he said.
Canadian ETF maker shares new cannabis additions
Horizons ETFs Management (Canada) completed its quarterly rebalancing for two of its highlight cannabis funds, the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) and the Horizons US Marijuana Index ETF (NEO:HMUS).
Steve Hawkins, president and CEO of Horizons ETFs, offered his own commentary on the state of cannabis investments in both the US and Canada.
For HMMJ, Hawkins said Canada has “largely languished, with valuations further exasperated by recent market volatility.” When it comes to the US market, the ETF executive said it no longer seems like 2021 will see any kind of significant legalization efforts.
“While it looks like America’s ‘marijuana moment’ won’t happen in 2021, there are still several initiatives underway that are paving the way for broader liberalization in the United States,” Hawkins said.
For HMMJ the new additions to the portfolio are:
- Grove (NASDAQ:GRVI)
- India Globalization Capital (NYSE:IGC)
- IPower (NASDAQ:IPW)
- MYMD Pharmaceuticals (NASDAQ:MYMD)
- Power REIT (NYSE:PW)
These are the newly added stocks for HMUS:
- Ceres Acquisition (NEO:CERE)
- Glass House Brands (NEO:GLAS)
- Grove (NASDAQ:GRVI)
- iAnthus Capital Holdings (CSE:IAN)
- India Globalization Capital (NYSE:IGC)
Cannabis company news
- Tilray (NASDAQ:TLRY,TSX:TLRY) signed a national brokerage agreement with Great North Distributors to exclusively represent its adult-use cannabis products. “This agreement will further drive exceptional route-to-market efficiencies for our comprehensive portfolio of adult-use cannabis brands and innovative 2.0 products,” Irwin Simon, chairman and CEO of Tilray, said.
- Innovative Industrial Properties (NYSE:IIPR) confirmed a new acquisition deal for a 201,000 square foot industrial property in Desert Hot Springs, California, while also entering into a long-term lease with a company called Gold Flora. The deal is valued at US$51 million.
- The Green Organic Dutchman Holdings (CSE:TGOD,OTCQX:TGODF) sent its first commercial shipment to Australia for a lineup of medical cannabis products. “We remain laser-focused on execution as we chart the course for future growth, including opportunities in international markets,” CEO Sean Bovingdon said.
- Halo Collective (NEO:HALO,OTCQB:HCAND) told investors it has changed the compensation program for the company’s senior officers and directors. All compensation for the remainder of 2021 will be handled in common shares of the company. The company expects to save US$2.1 million in cash. “What better way to demonstrate our confidence — and alignment with shareholders — than for the 15 most senior leaders of the Company to all elect to take their compensation in Common Shares in lieu of cash,” Kiran Sidhu, CEO of Halo, said.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Avicanna Completes Commercial Export of CBD Isolate and CBD Full Spectrum Psychoactive Derivatives from Colombia to Chile
- The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.
Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.
The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.
To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
About Aureus ™
Avicanna’s supply chain business units are based in Santa Marta, Colombia and are primarily dedicated to providing consistent source of cannabinoid raw materials for Avicanna’s current commercial products and pharmaceutical pipeline for the global marketplace.
Additionally, under the Aureus™ brand, standardized cannabis extracts and feminized seeds are made available to cultivation, cosmetic and pharmaceutical partners around the world. Aureus branded products are cultivated, extracted, and manufactured by Avicanna’s subsidiaries in Colombia where they benefit from optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients economically and sustainably and include a range of extracts of CBD, THC and rare cannabinoids such as CBG. Avicanna’s supply chain business also benefits from federally regulated legislation in Colombia where the company is well positioned to be a global supplier of the less competitive psychoactive extracts including CBD and THC crude oil to meet the growing global demand.
Avicanna is a commercial stage Canadian biopharmaceutical company and an established leader in cannabinoid research, development, and evidence-based products for the global consumer, medical, and pharmaceutical market segments. Avicanna conducts its research in Canada including its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada, located in the MaRS Discovery District, and in collaboration with leading Canadian academic and medical institutions. Avicanna has established an industry leading scientific platform including advanced R&D and clinical development which has led to the commercialization of over twenty products across four main market segments:
- RHO Phyto™: these medical and wellness products are an advanced line of pharmaceutical-grade cannabis products containing varying ratios of CBD and THC. The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. These products are developed using pharmaceutical drug development processes and are supported with pre-clinical data. The advanced formulary is marketed with consumer, patient and medical community education and training.
- Pura H&W™: these registered, clinically tested, cosmetic products include a portfolio of functional CBD consumer derma-cosmetic and topical products.
- Aureus™: as a part of Avicanna’s vertical integration based out of Santa Marta, Colombia its supply chain business units are primarily dedicated to providing consistent source of cannabinoid raw materials for Avicanna and its global partner’s food, cosmetic, medical and pharmaceutical needs. Aureus branded products are cultivated, extracted, and manufactured by Avicanna’s subsidiaries in Colombia where they benefit from optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients economically, organically, and sustainably and include a range of CBD, THC and rare cannabinoids such as CBG extracts and standardized seeds. Company is well positioned to be a global supplier of cannabinoid raw materials demand and has already successfully exported its products to over 10 countries in 4 continents.
- Pharmaceutical pipeline: leveraging from the company’s scientific platform, vertical integration, and real-world evidence, Avicanna has established a pipeline of indication specific cannabinoid-based drug candidates that are in various stages of clinical development and commercialization. Avicanna’s drug candidates are in pre-clinical stage and are dedicated to providing solutions for unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders.
SOURCE Avicanna Inc.
The Company posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA .
Cautionary Note Regarding Forward-Looking Information and Statement
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate” “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the SMGH’s ability to maintain its licenses to cultivate cannabis, or SMGH’s ability to export Cannabis Derivatives to Chile. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated September 3, 2021 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
News Provided by GlobeNewswire via QuoteMedia
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .
Following the release of its second quarter fiscal year 2022 financial results, Canopy Growth will host an audio webcast with David Klein , CEO and Mike Lee , EVP & CFO at 10:00 AM Eastern Time on November 5, 2021 .
A live audio webcast will be available at:
A replay will be accessible by webcast until 11:59 PM ET on February 3, 2022 at:
About Canopy Growth Corporation
Canopy Growth (TSX: WEED , NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany . Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada , the United States , and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional hemp-derived CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com .
Notice Regarding Forward Looking Statements
This press release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable U.S. and Canadian securities laws (collectively, “forward-looking statements”), which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use
of such terms and phrases as “intend,” “goal,” “strategy,” “estimate,” “expect,” “project,” “projections,” “forecasts,” “plans,” “seeks,” “anticipates,” “potential,” “proposed,” “will,” “should,” “could,” “would,” “may,” “likely,” “designed to,” “foreseeable future,” “believe,” “scheduled” and other similar expressions. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Forward–looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those forward–looking statements and the forward–looking statements are not guarantees of future performance. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. A discussion of some of the material factors applicable to Canopy Growth Corporation (“Canopy”) can be found under the section entitled “Risk Factors” in Canopy’s Annual Report on Form 10-K for the year ended March 31, 2021 , filed with the Securities and Exchange Commission and with applicable Canadian securities regulators, as such factors may be further updated from time to time in its periodic filings with the Securities and Exchange Commission and with applicable Canadian securities regulators, which can be accessed at www.sec.gov/edgar and www.sedar.com , respectively. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the filings. Any forward–looking statement included in this press release is made as of the date of this press release and, except as required by law, Canopy disclaims any obligation to update or revise any forward– looking statement. Readers are cautioned not to put undue reliance on any forward–looking statement. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
View original content to download multimedia: https://www.prnewswire.com/news-releases/canopy-growth-to-report-q2-2022-financial-results-on-november-5-2021-301406364.html
SOURCE Canopy Growth Corporation
News Provided by Canada Newswire via QuoteMedia
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/
Sunnyside Wyomissing opens Friday, October 22, marking Cresco Labs’ first store in the city of Reading and fifth location in Pennsylvania.
Sunnyside Wyomissing is located at 208 N Park Rd. Unit #1. The nearly 6,000 sq. foot dispensary is across from The Knitting Mills, a redevelopment mixed-use business and retail campus, and minutes away from U.S. Route 222/US 422 for easy access to daily commuters.
The new store will offer premium quality products from Cresco Labs’ wholesale brands Cresco, Supply and Remedi, as well as other top brands. Products include flower; vape products like liquid live resin; concentrates; Rick Simpson Oil (RSO); topicals like lotion; capsules; and tinctures. It will also sell branded merchandise and accessories including vaporizers, vape batteries and more.
Sunnyside Wyomissing will serve patients with a medical card issued by the Pennsylvania Department of Health. Patients can place product orders online through the Sunnyside.shop website or visit Sunnyside to speak with wellness advisors for purchasing assistance. Regular store hours are Monday through Thursday and Sunday, 9AM to 6PM, and Friday and Saturday, 9AM to 7PM.
For more information about Sunnyside, visit www.sunnyside.shop .
About Cresco Labs Inc.
Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy’s Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com .
Forward Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
Jason Erkes, Cresco Labs
Chief Communications Officer
Jake Graves, Cresco Labs
Manager, Investor Relations
For general Cresco Labs inquiries:
News Provided by Business Wire via QuoteMedia
The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.
Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.
And with a wealth of data to back up its possible delivery methods, cannabis will only continue to grow as an item in the consumer packaged goods sector.
The Investing News Network (INN) spoke with several experts overseeing cannabis research to discuss what lies ahead in the market, as well as the urgent need to generate additional data.
More data needed to unearth potential of cannabis
Ashley Chiu of EY Canada told INN the business of using novel research tactics to explore the full impact of cannabis provides a precious opportunity to validate the plant in the eyes of skeptics.
“I think there’s been a lot of harm associated with cannabis, but not necessarily all of the data to back it up,” said the cannabis strategy advisor.
This past summer, the cannabis team at EY Canada published a new report examining the need for more profound research on the cannabis plant — not just for medical uses, but as a way to expand cannabis consumption options in a broad sense.
Joel Alden, a partner at EY Canada, previously told INN there is an untapped world of opportunity attached to the cannabis plant and its molecules.
In its optimistic report, the firm indicates that savvy businesses within the space will race to explore and develop the next stages of consumption beyond smoking and eating.
When asked about what other uses or possibilities lie ahead, Chiu told INN the idea of creating personalized nutraceuticals from the cannabis plant could be key to broadening consumer numbers.
She highlighted the need to explore more cannabinoids within the cannabis plant, as early indications have shown promise in helping people with sleep issues.
Plainly speaking, further broad cannabis research is needed, according to the EY expert. Chiu explained that research outside the clinical context is critical as well in order to gain a better understanding of cannabis compounds and the effects these have on the human body.
“(It) sets the foundation of where the industry will go, and I think once we get all of this validated research it will really open up the opportunity of the commercial prospects for cannabis or its various constituents,” Chiu said.
Medical cannabis uses stuck outside the mainstream
Stephen Murphy, co-founder and CEO of leading cannabis research company Prohibition Partners, told INN he’s mostly intrigued by any examination of cannabis as a pain management agent.
Similarly to Chiu, Murphy sees the advancement of cannabis research as one of the pillars needed to transform the drug’s reputation across the world.
When it comes to pain management, if a medical candidate can gain relevancy, Murphy said he could see mainstream healthcare adopt the medical benefits of the plant in a more significant way.
“If it does, that gets cannabis over the edge in mainstream healthcare where suddenly there is (validation) for one of the most common issues,” said Murphy. “It’s no longer just a specialty product.”
His firm recently issued the second edition of its market report on pharmaceutical cannabis. Titled “The Pharmaceutical Cannabis Report,” it was authored by Prohibition Partners analyst Conor O’Brien.
In an executive summary of the report, Prohibition Partners points to the following four drugs as the most exciting prospects in the cannabis pharmaceutical pipeline: Epidiolex and Sativex, which were both developed recently by GW Pharmaceuticals, and Marinol and Cesamet, which have a long history and are researched regularly.
Legislation affecting support for cannabis research
One aspect to monitor when it comes to any ramp up in cannabis research practices is the progress of the US regulatory landscape surrounding the drug.
“I don’t necessarily think that just because the US legalizes, all these other countries will automatically (do the same), but I think it opens the door to that conversation,” Chiu told INN.
The US is involved in a convoluted political process to move ahead with some kind of cannabis reform. The drug remains a Schedule I substance in the eyes of the federal government, but state liberties have created domestic markets where companies may set up dispensaries, growing facilities and other cannabis business opportunities.
As of October of this year, 19 states had introduced an adult-use cannabis program into their everyday operations, allowing for legal sales and business operations.
At the federal level, the struggle to get cannabis into a new standing continues. This aspect has a direct correlation to further investigation of the drug, Murphy told INN.
“Legislation doesn’t really support … it’s still very restrictive in terms of conducting trials around cannabis,” Murphy explained to INN, taking a more global perspective since Prohibition Partners evaluates the entire cannabis space worldwide.
At the end of the day, the ability the US has to change perspectives around the world is undeniable.
“When you look at the impact that the US has on global affairs, other industries, culture, societal shifts, I think they lead a lot of that,” Chiu said.
In its report, Prohibition Partners indicates that current regulations have helped patients access regulated medical cannabis products fairly easily. That likely won’t be the same for future advanced cannabis drugs, which may need to be prescribed by a doctor.
“It is likely that the medical use of cannabinoids will become more closely aligned to traditional medical practices in coming years, in terms of patient-doctor relations and the precision of dosing,” the market report from the firm reads.
The researchers at Prohibition Partners expect global legalization of adult-use cannabis to help bring along this new age of medical use of cannabinoids.
The need to research the cannabis plant and its molecules goes farther than just expanding the industry. Uncovering new data could help point the entire industry towards unprecedented levels of confidence among people both inside and outside the market.
A new world of cannabis business is just around the corner, according to experts, and expanded research on the plant’s medical benefits may help get it there.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.